BioMarin to Participate in Upcoming Investor Conferences

BioMarin Pharmaceutical (NASDAQ: BMRN) announced that management will present at three upcoming investor conferences during November 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

BioMarin Pharmaceutical (NASDAQ: BMRN) announced that management will present at three upcoming investor conferences during November 2026.

The presentations are scheduled for the Stifel Healthcare Conference on November 11 at 3:20 pm EST, UBS Global Biopharma Conference on November 16 at 9:20 am GMT, and Jefferies Global Healthcare Conference on November 17 at 11:30 am GMT. Live audio webcasts and limited-time archives will be available on the company’s investor website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/04/2026 - 09:00 AM EST

Stifel Healthcare Conference, November 11 at 3:20 pm EST
UBS Global Biopharma Conference, November 16 at 9:20 am GMT
Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT

SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.

An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.